MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Panbela Therapeutics, Inc.

< Previous 1 2 Next >
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Poster Presentation at American Association for Cancer Research:
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Transfer to OTCQB Market
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Closing of Approximately $9.0 Million Public Offering
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-Market
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela to Present at the LD Micro Investor Conference
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story